Deerfield Management Company, L.P. is a New York City-based investment firm founded in 1994. It focuses on healthcare investments, managing more than $16 billion in assets as of December 2025 across life sciences, biotechnology, medical devices, diagnostics, digital health, and health services. The firm supports over 200 public and private portfolio companies at all stages through flexible funding models, company-building initiatives, and specialized research teams. It also engages in philanthropy via affiliated not-for-profit activities aimed at advancing healthcare innovation.
Also known as Deerfield and Deerfield Management Company.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
